-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Benzinga·10/14/2026 12:30:11
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.